Lupin has entered into an Exclusive Licensing Agreement with Valorum Biologics (Valorum), a biosimilar specialist in the U.S., for its biosimilar Armlupeg (pegfilgrastim-unne). Under the terms of the agreement, Valorum will advance the commercialization and distribution of Armlupeg (pegfilgrastim-unne) in the United States.
Lupin will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales. Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
